Acer Therapeutics Inc

Acer Therapeutics — Opexa Therapeutics — Q3 2013 Earnings Presentation

7 slides from Acer Therapeutics's earnings presentation, Nov 7, 2013

  1. Slide 1: Precision Immunotherapy

    ™ Precision Immunotherapy

  2. Slide 2: Forward-Looking Statements

    Slide: 2 Title: Forward-Looking Statements Other Placeholder: This earnings presentation contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amen

  3. Slide 3: Tcelna Addressing the Root Cause of Multiple Sclerosis

    Slide: 3 Title: Tcelna Addressing the Root Cause of Multiple Sclerosis Preventing Demyelination and Enabling Remyelination Myelin Reactive T-cells (MRTC) cross the blood brain barrier, enter the brain, bind to antigen presenting cells (APC) causing release of pro-inflammatory cytokines which lead to

  4. Slide 4: Abili-T: Landmark trial in SPMS

    Slide: 4 Title: Abili-T : Landmark trial in SPMS Other Placeholder: Abili-T Phase IIb clinical trial in SPMS is ongoingDouble-blind, 1:1 randomized, placebo-controlledTwo annual courses of personalized therapyInclusion criteria: Secondary Progressive MS with EDSS of 3 to 6100 patients enrolled as of

  5. Slide 5: Balance Sheet Highlights

    Slide: 5 Other Placeholder: 5 Title: Balance Sheet Highlights Sept 2013 Dec 2012 Assets Cash & Cash Equivalents $20,172,485 $592,004 Property Plant & Equipment $1,226,511 $1,265,041 Deferred Financing Costs net $‐ $211,479 Liabilities & Shareholders’ Equity Accounts Payable $914,317 $412,096 Shareho

  6. Slide 6: Income Statement

    Slide: 6 Other Placeholder: 6 Title: Income Statement Sept 2013 Sept 2012 Revenues $348,837 ‐ R&D Expense $2,494,463 $1,455,938 General & Administrative $626,668 $532,474 Interest Expense $346,239 $151,029 Loss on Extinguishment of debt $2,518,912 $‐ Net Loss $5,723,932 $2,357,783 Basic and diluted

  7. Slide 7: Investment Thesis

    Slide: 7 Title: Investment Thesis Other Placeholder: T-cell platform company with Fast Track designation in SPMSStrong Intellectual property with 50 issued patents Esteemed Scientific Advisory Board Precision Immunotherapy potentially optimizes benefit-risk profileTargeting an unmet medical need in

Opexa Therapeutics — Q3 2013 Earnings Presentation on 6ix